Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Shanghai Pharmaceuticals, Primavera's $239M Buyout Of Australia's Vitaco Gets FIRB Approval
Private Equity

Shanghai Pharmaceuticals, Primavera's $239M Buyout Of Australia's Vitaco Gets FIRB Approval

by chinamoneynetwork.com posted 2years ago 2276 views
A US$239 million deal led by Chinese drugmaker Shanghai Pharmaceuticals Holding Co., Ltd. and private equity firm Primavera Capital to acquire Australian vitamins maker Vitaco Holdings has won approval from Australia's Foreign Investment Review Board (FIRB), clearing a major roadblock and pushing the deal closer to completion.